Calidi Biotherapeutics, Inc. Finance Lease, Liability, Current
Calidi Biotherapeutics, Inc. (CLDI) had Finance Lease, Liability, Current of $167.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-13
- 2026-06-30: Finance Lease, Liability, Current $167.00K.
- 2026-03-31: Finance Lease, Liability, Current $154.00K.
- 2025-12-31: Finance Lease, Liability, Current $111.00K.
- 2025-09-30: Finance Lease, Liability, Current $112.00K.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2026-06-30 | $167.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $154.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $111.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $112.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $113.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $69.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $66.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $69.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $68.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $74.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $81.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $62.00K 10-Q · filed 2024-11-12 |
| 2023-06-30 | $70.00K 10-Q · filed 2024-08-13 |
| 2023-03-31 | $71.00K 10-Q · filed 2024-05-14 |
| 2022-12-31 | $72.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | $47.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |